Mounia Sedrati
Research Subjects
Mounia Sedrati has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Fatima Zahra Samet Bouhaik
Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France
4 shared publications - Fouad Mohammed Sekkal
Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France
4 shared publications - Valeria Trivelloni
Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France
4 shared publications - Yassine Bencharef
Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France
4 shared publications - Insaf Chouarfia
Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France
3 shared publications - Dario Bottigliero
Department of Cardiology, Centre Hospitalier General Victor Jousselin de Dreux, 28100 Dreux, France
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (8) , 397
Forward Dynamics: Modern Insights into Mitral Systolic Anterior Motion
Systolic anterior motion (SAM) of the mitral valve can occur either in association with or in the absence of hypertrophic obstructive cardiomyopathy (HOCM). SAM induces dynamic left ventricular outflow tract obstruction (LVOTO) and, in the majority of cases, is associated with a substantial degree of mitral regurgitation (MR) that significantly impacts patient morbidity and mortality. This narrative review explores the contemporary understanding of the pathophysiology, diagnosis, and management of SAM, focusing particularly on surgical strategies and the novel therapeutic class of cardiac myosin inhibitors. Extended septal myectomy remains the gold-standard treatment for HOCM-related SAM, yielding superior long-term outcomes compared to alcohol septal ablation (ASA). Advanced imaging modalities, including three-dimensional transesophageal echocardiography (3D-TEE), enable precise pre-operative characterization of the mitral valve apparatus. Some patients may benefit from septal reduction strategies while concomitant mitral valve interventions are generally reserved for highly selected cases with intrinsic valve pathology or persistent residual SAM, thereby avoiding unnecessary valvular manipulation and its potential hemodynamic risks. Mavacamten, a selective cardiac myosin inhibitor, represents an important advance in pharmacological management, achieving a mean LVOT gradient reduction of 37.2 mmHg in symptomatic patients. Furthermore, data from the MARVEL registry confirm the real-world clinical efficacy of mavacamten in obstructive hypertrophic cardiomyopathy, with 86% of patients successfully down-staged to NYHA functional class I–II. Although ASA serves as a viable alternative to surgery, it entails a higher risk of conduction abnormalities requiring permanent pacemaker implantation and subsequent re-intervention. Beyond classical hypertrophic SAM, this review addresses the diagnosis and management of post-mitral repair complications and non-hypertrophic variants. Optimal management and risk stratification remain an evolving field requiring a multidisciplinary Heart Team approach, leverage of advanced imaging, and adoption of novel medical therapies. Interventional strategies must be carefully tailored to maximize the efficacy-to-safety profile on an individualized patient basis.
- 19 August 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (8) , 397
Open AccessForward Dynamics: Modern Insights into Mitral Systolic Anterior Motion
Systolic anterior motion (SAM) of the mitral valve can occur either in association with or in the absence of hypertrophic obstructive cardiomyopathy (HOCM). SAM induces dynamic left ventricular outflow tract obstruction (LVOTO) and, in the majority of cases, is associated with a substantial degree of mitral regurgitation (MR) that significantly impacts patient morbidity and mortality. This narrative review explores the contemporary understanding of the pathophysiology, diagnosis, and management of SAM, focusing particularly on surgical strategies and the novel therapeutic class of cardiac myosin inhibitors. Extended septal myectomy remains the gold-standard treatment for HOCM-related SAM, yielding superior long-term outcomes compared to alcohol septal ablation (ASA). Advanced imaging modalities, including three-dimensional transesophageal echocardiography (3D-TEE), enable precise pre-operative characterization of the mitral valve apparatus. Some patients may benefit from septal reduction strategies while concomitant mitral valve interventions are generally reserved for highly selected cases with intrinsic valve pathology or persistent residual SAM, thereby avoiding unnecessary valvular manipulation and its potential hemodynamic risks. Mavacamten, a selective cardiac myosin inhibitor, represents an important advance in pharmacological management, achieving a mean LVOT gradient reduction of 37.2 mmHg in symptomatic patients. Furthermore, data from the MARVEL registry confirm the real-world clinical efficacy of mavacamten in obstructive hypertrophic cardiomyopathy, with 86% of patients successfully down-staged to NYHA functional class I–II. Although ASA serves as a viable alternative to surgery, it entails a higher risk of conduction abnormalities requiring permanent pacemaker implantation and subsequent re-intervention. Beyond classical hypertrophic SAM, this review addresses the diagnosis and management of post-mitral repair complications and non-hypertrophic variants. Optimal management and risk stratification remain an evolving field requiring a multidisciplinary Heart Team approach, leverage of advanced imaging, and adoption of novel medical therapies. Interventional strategies must be carefully tailored to maximize the efficacy-to-safety profile on an individualized patient basis.
- Open Access
- 21 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4819
Small Hearts, Big Clues: A Narrative Review on Sex-Related Disparities in the Diagnosis and Management of Cardiac Amyloidosis in Women
Background: Amyloidosis is an infiltrative cardiomyopathy caused by amyloid deposition into the myocardium. In recent years, recognition of this treatable cause of heart failure has increased. There are striking sex differences in the diagnosis, clinical course and outcome of the disease. Notably, women have a worse prognosis than men with similar amounts of cardiac involvement. Methods: This review provides an overview of the current state of knowledge regarding the epidemiology, clinical features, diagnosis and treatment of amyloid heart disease. The differences observed between men and women are discussed, and recent advances in the field are highlighted. Results: Compared to men, women are generally older at diagnosis, appear to have less severe cardiac disease at the time of impairment and are more frequently diagnosed late. The less apparent disease manifestations in women may be responsible for the delay in diagnosis. Moreover, women may be underdiagnosed when sex-neutral diagnostic criteria are used. Conclusions: Addressing diagnostic disparities may require the use of sex-specific diagnostic thresholds, as well as a more expansive use of multimodality imaging. Future clinical trials should aim to enroll a greater number of female participants to inform optimal therapeutic approaches and to define the sex-specific disease phenotype for this increasingly treatable disease.
- 21 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4819
Open AccessSmall Hearts, Big Clues: A Narrative Review on Sex-Related Disparities in the Diagnosis and Management of Cardiac Amyloidosis in Women
Background: Amyloidosis is an infiltrative cardiomyopathy caused by amyloid deposition into the myocardium. In recent years, recognition of this treatable cause of heart failure has increased. There are striking sex differences in the diagnosis, clinical course and outcome of the disease. Notably, women have a worse prognosis than men with similar amounts of cardiac involvement. Methods: This review provides an overview of the current state of knowledge regarding the epidemiology, clinical features, diagnosis and treatment of amyloid heart disease. The differences observed between men and women are discussed, and recent advances in the field are highlighted. Results: Compared to men, women are generally older at diagnosis, appear to have less severe cardiac disease at the time of impairment and are more frequently diagnosed late. The less apparent disease manifestations in women may be responsible for the delay in diagnosis. Moreover, women may be underdiagnosed when sex-neutral diagnostic criteria are used. Conclusions: Addressing diagnostic disparities may require the use of sex-specific diagnostic thresholds, as well as a more expansive use of multimodality imaging. Future clinical trials should aim to enroll a greater number of female participants to inform optimal therapeutic approaches and to define the sex-specific disease phenotype for this increasingly treatable disease.
- Open Access
- 13 May 2026
- Published by MDPI AG in Preprints.org
Not So Rare After All: Rethinking Hereditary Transthyretin Amyloidosis
Background: Transthyretin amyloidosis (ATTR) is a rare, often underdiagnosed and undertreated, autosomal dominantly inherited, progressive disease that affects multiple systems of the body. It results from the extracellular accumulation of misfolded transthyretin (TTR) protein as insoluble amyloid fibrils, predominantly causing cardiomyopathy, polyneuropathy or mixed phenotypes. It can occur in a hereditary form (ATTRv) and in a wild-type form (ATTRwt), with over 150 different pathogenic mutations having been identified worldwide. The clinical presentation is highly variable, leading to a diagnostic delay of 2–5 years. Transthyretin (TTR) amyloidosis is an inherited disease for which recent advances in pathogenesis, diagnosis and treatment have revolutionized its management. Objectives: The aims of this review are to provide an update on the epidemiology and genotype-phenotype correlation, on current diagnostic techniques and on emerging and individualized treatments for this rare hereditary disease. Particular attention will be given to the early diagnosis Methods: A systematic literature search was conducted across major databases to identify studies addressing clinical characteristics, diagnostic modalities, and treatment outcomes in hereditary and wild-type ATTR amyloidosis. Registry data from THAOS and other multinational cohorts were analyzed to evaluate phenotypic variability across genotypes and geographic regions. Results: Clinical presentation of TTR related amyloidosis (h-Amyloid) can range from early onset to late onset with late onset having worse neurological and cardiac involvement at time of diagnosis. The Val30Met mutation is the most common TTR mutation worldwide, however patients with non-V30M mutations can have very different presentations of h-amyloidosis. Identifying “red flag” symptoms in a patient with suspicious clinical presentation can initiate correct diagnostic pathway. Non-invasive imaging, especially bone scintigraphy, has greatly facilitated the diagnosis of patients with Transthyretin related cardiac amyloidosis (ATTR-CM). First generation h-amyloid treatments or TTR stabilizers such as tafamidis have been shown to significantly improve survival in patients with h-amyloidosis. The second generation treatments such as RNA silencers (patisiran, vutrisiran, inotersen, eplontersen) have been shown to halt the disease progression. Present data from small to moderate-sized patient cohorts demonstrate that TTR-targeting therapy is associated with reduction of cardiovascular events and improvement in survival compared with current standard of care. Early recognition of key clinical features and application of a diverse diagnostic strategy, in conjunction with timely initiation of disease-modifying therapy, are critical to optimal management of patients with hereditary transthyretin (ATTR) amyloidosis. Conclusions: The therapeutic options have evolved and improved in recent years, and with current diagnostic tools, the opportunity to alter the natural history of a disease that was once invariably fatal is better than ever. Because the disease is systemic, a thorough, multidisciplinary approach to patient management is ideal.
- 13 May 2026
- Published by MDPI AG in Preprints.org
Open AccessNot So Rare After All: Rethinking Hereditary Transthyretin Amyloidosis
Background: Transthyretin amyloidosis (ATTR) is a rare, often underdiagnosed and undertreated, autosomal dominantly inherited, progressive disease that affects multiple systems of the body. It results from the extracellular accumulation of misfolded transthyretin (TTR) protein as insoluble amyloid fibrils, predominantly causing cardiomyopathy, polyneuropathy or mixed phenotypes. It can occur in a hereditary form (ATTRv) and in a wild-type form (ATTRwt), with over 150 different pathogenic mutations having been identified worldwide. The clinical presentation is highly variable, leading to a diagnostic delay of 2–5 years. Transthyretin (TTR) amyloidosis is an inherited disease for which recent advances in pathogenesis, diagnosis and treatment have revolutionized its management. Objectives: The aims of this review are to provide an update on the epidemiology and genotype-phenotype correlation, on current diagnostic techniques and on emerging and individualized treatments for this rare hereditary disease. Particular attention will be given to the early diagnosis Methods: A systematic literature search was conducted across major databases to identify studies addressing clinical characteristics, diagnostic modalities, and treatment outcomes in hereditary and wild-type ATTR amyloidosis. Registry data from THAOS and other multinational cohorts were analyzed to evaluate phenotypic variability across genotypes and geographic regions. Results: Clinical presentation of TTR related amyloidosis (h-Amyloid) can range from early onset to late onset with late onset having worse neurological and cardiac involvement at time of diagnosis. The Val30Met mutation is the most common TTR mutation worldwide, however patients with non-V30M mutations can have very different presentations of h-amyloidosis. Identifying “red flag” symptoms in a patient with suspicious clinical presentation can initiate correct diagnostic pathway. Non-invasive imaging, especially bone scintigraphy, has greatly facilitated the diagnosis of patients with Transthyretin related cardiac amyloidosis (ATTR-CM). First generation h-amyloid treatments or TTR stabilizers such as tafamidis have been shown to significantly improve survival in patients with h-amyloidosis. The second generation treatments such as RNA silencers (patisiran, vutrisiran, inotersen, eplontersen) have been shown to halt the disease progression. Present data from small to moderate-sized patient cohorts demonstrate that TTR-targeting therapy is associated with reduction of cardiovascular events and improvement in survival compared with current standard of care. Early recognition of key clinical features and application of a diverse diagnostic strategy, in conjunction with timely initiation of disease-modifying therapy, are critical to optimal management of patients with hereditary transthyretin (ATTR) amyloidosis. Conclusions: The therapeutic options have evolved and improved in recent years, and with current diagnostic tools, the opportunity to alter the natural history of a disease that was once invariably fatal is better than ever. Because the disease is systemic, a thorough, multidisciplinary approach to patient management is ideal.
- Open Access
- 5 May 2026
- Published by MDPI AG in Preprints.org
Small Hearts, Big Clues: Amyloidosis in Women
Background Amyloidosis is an infiltrative cardiomyopathy caused by amyloid deposition into the myocardium. In recent years, recognition of this treatable cause of heart failure has increased. There are striking sex differences in diagnosis, clinical course, and outcome. Notably, women have a worse prognosis than men with similar amounts of cardiac involvement. Methods This review provides an overview of the current state of knowledge on the epidemiology, clinical features, diagnosis and treatment of amyloid heart disease. The differences observed between men and women are discussed and recent advances in the field are highlighted. Results Compared with men, women are generally older at diagnosis, appear to have less severe cardiac disease at time of impairment and are given a late diagnosis. The less apparent disease in women may be responsible for the delay in diagnosis. Women may be under-diagnosed using neutral sex diagnostic criteria. Conclusions Addressing diagnostic disparities may require the use of sex-specific diagnostic thresholds, as well as a more expansive use of multimodality imaging. Future studies trials should aim to enroll greater numbers of female participants to inform optimal therapeutic approaches and to define the sex-specific disease phenotype for this increasingly treatable disease.
- 5 May 2026
- Published by MDPI AG in Preprints.org
Open AccessSmall Hearts, Big Clues: Amyloidosis in Women
Background Amyloidosis is an infiltrative cardiomyopathy caused by amyloid deposition into the myocardium. In recent years, recognition of this treatable cause of heart failure has increased. There are striking sex differences in diagnosis, clinical course, and outcome. Notably, women have a worse prognosis than men with similar amounts of cardiac involvement. Methods This review provides an overview of the current state of knowledge on the epidemiology, clinical features, diagnosis and treatment of amyloid heart disease. The differences observed between men and women are discussed and recent advances in the field are highlighted. Results Compared with men, women are generally older at diagnosis, appear to have less severe cardiac disease at time of impairment and are given a late diagnosis. The less apparent disease in women may be responsible for the delay in diagnosis. Women may be under-diagnosed using neutral sex diagnostic criteria. Conclusions Addressing diagnostic disparities may require the use of sex-specific diagnostic thresholds, as well as a more expansive use of multimodality imaging. Future studies trials should aim to enroll greater numbers of female participants to inform optimal therapeutic approaches and to define the sex-specific disease phenotype for this increasingly treatable disease.